Biostem US Corporation President Announces Study Results on Stem Cell Hair Loss Treatment

Biostem US Corporation a regenerative medicine company,
announced completion of a two year study on treating Alopecia
Areata, thought to be an autoimmune disease, which causes sudden
hair loss. On October 28th, John Satino, President of Biostem,
announced results of a two year consumer study conducted at a
Biostem affiliate clinic in Florida at The international Stem Cell
Cicatrical Alopecia Symposium. The Symposium was held in
Bethesda, Maryland and sponsored by Case Western Reserve School of
Medicine and The National Institutes of Health Rare Disease
Research Office. The study involved 700 patients, with results
showing renewed hair growth in 80% of the participants. The
treatment, developed by Biostem, includes a combination of the
patients own blood, utilization of growth factors, laser treatments
for bio-photo stimulation, and a nutraceutical designed to
stimulate hair follicle growth.